Pacific Biosciences of California (PACB) Competitors $1.20 +0.03 (+2.14%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PACB vs. TXG, HBIO, TMO, A, MTD, WAT, ILMN, TECH, CRL, and BIOShould you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bio-Rad Laboratories (BIO). Pacific Biosciences of California vs. Its Competitors 10x Genomics Harvard Bioscience Thermo Fisher Scientific Agilent Technologies Mettler-Toledo International Waters Illumina Bio-Techne Charles River Laboratories International Bio-Rad Laboratories Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership. Does the media refer more to PACB or TXG? In the previous week, 10x Genomics had 19 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 21 mentions for 10x Genomics and 2 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.79 beat Pacific Biosciences of California's score of 0.73 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 6 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PACB or TXG? Pacific Biosciences of California currently has a consensus price target of $1.90, indicating a potential upside of 57.68%. 10x Genomics has a consensus price target of $13.65, indicating a potential upside of 3.16%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, research analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacific Biosciences of California 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.4310x Genomics 1 Sell rating(s) 8 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has preferable earnings and valuation, PACB or TXG? 10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacific Biosciences of California$154.01M2.35-$309.85M-$2.29-0.5310x Genomics$610.78M2.70-$182.63M-$0.70-18.91 Do insiders & institutionals have more ownership in PACB or TXG? 84.7% of 10x Genomics shares are owned by institutional investors. 2.4% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is PACB or TXG more profitable? 10x Genomics has a net margin of -13.13% compared to Pacific Biosciences of California's net margin of -336.40%. 10x Genomics' return on equity of -12.88% beat Pacific Biosciences of California's return on equity.Company Net Margins Return on Equity Return on Assets Pacific Biosciences of California-336.40% -66.75% -16.90% 10x Genomics -13.13%-12.88%-10.03% Which has more risk and volatility, PACB or TXG? Pacific Biosciences of California has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500. Summary10x Genomics beats Pacific Biosciences of California on 13 of the 16 factors compared between the two stocks. Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PACB vs. The Competition Export to ExcelMetricPacific Biosciences of CaliforniaMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$361.95M$6.65B$5.75B$10.27BDividend YieldN/A1.20%5.73%4.60%P/E Ratio-0.5325.9475.1826.37Price / Sales2.35174.96457.0688.69Price / CashN/A22.1825.8129.91Price / Book0.654.9613.256.28Net Income-$309.85M$176.38M$3.29B$270.67M7 Day Performance-3.60%5.82%0.72%2.79%1 Month Performance-8.02%7.36%4.58%6.01%1 Year Performance-33.43%11.13%73.44%26.05% Pacific Biosciences of California Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PACBPacific Biosciences of California2.3433 of 5 stars$1.20+2.1%$1.90+59.0%-35.4%$358.94M$154.01M-0.52730Gap UpTXG10x Genomics3.6069 of 5 stars$13.93-0.2%$13.54-2.8%-43.5%$1.73B$644.47M-19.901,240Analyst DowngradeHBIOHarvard Bioscience3.9463 of 5 stars$0.45-4.9%$3.00+559.9%-84.7%$20.24M$94.14M-0.35490Short Interest ↑TMOThermo Fisher Scientific4.9782 of 5 stars$487.11-1.1%$589.38+21.0%-21.5%$183.94B$42.88B28.17125,000Positive NewsAAgilent Technologies4.5788 of 5 stars$128.13-0.5%$139.25+8.7%-10.3%$36.32B$6.51B30.0817,900Positive NewsAnalyst ForecastAnalyst RevisionMTDMettler-Toledo International4.1511 of 5 stars$1,314.38+0.7%$1,311.11-0.2%-9.0%$27.07B$3.87B33.2817,300Positive NewsWATWaters4.7771 of 5 stars$309.58+1.1%$378.73+22.3%-9.3%$18.43B$2.96B27.927,600ILMNIllumina4.8327 of 5 stars$98.18-0.8%$123.06+25.3%-26.4%$15.09B$4.37B12.439,030Positive NewsTECHBio-Techne4.9909 of 5 stars$54.11-0.6%$70.42+30.1%-31.4%$8.48B$1.22B117.633,100Positive NewsCRLCharles River Laboratories International4.612 of 5 stars$161.97-1.2%$175.69+8.5%-22.8%$7.97B$4.05B-121.7820,100Positive NewsAnalyst UpgradeBIOBio-Rad Laboratories4.8045 of 5 stars$290.32-1.7%$333.50+14.9%-14.1%$7.86B$2.55B24.757,700Positive News Related Companies and Tools Related Companies TXG Competitors HBIO Competitors TMO Competitors A Competitors MTD Competitors WAT Competitors ILMN Competitors TECH Competitors CRL Competitors BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PACB) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PACB Stock Alerts